Neurocrine Biosciences Names Andrew Ratz as CTO, Drives Biologics and Device Expansion
Neurocrine Biosciences promoted Andrew Ratz, Ph.D., to Chief Technical Operations Officer, tasking him with leading global technical development, manufacturing and supply chain functions as the company expands into biologics and device-based therapies. Ratz brings nearly 30 years at Eli Lilly, overseeing development of 25+ medicines across modalities.
1. Executive Appointment
Neurocrine Biosciences has elevated Andrew Ratz, Ph.D., to the newly created Chief Technical Operations Officer position, integrating him into the executive management team effective immediately.
2. Role and Responsibilities
In his CTO role, Ratz will lead global technical development, manufacturing and supply chain operations, overseeing Neurocrine’s shift beyond small molecules into biologics and device-based therapies.
3. Prior Experience and Track Record
Ratz joined Neurocrine in January 2025 as Senior Vice President of Drug Development, Delivery and Device. He previously spent nearly 30 years at Eli Lilly, overseeing development of more than 25 medicines across various therapeutic modalities.
4. Strategic Impact
The appointment aims to strengthen Neurocrine’s production capabilities and support planned expansion into complex biologic and device markets. Ratz’s leadership is expected to accelerate technical development and enhance supply reliability.